Costs Associated with Exit or Disposal Activities

Chronoscale Corp Form 8-K Summary

Business Context and Reporting Period

Chronoscale Corporation (Nasdaq: CHRN), a Nevada corporation, filed this Current Report on Form 8-K on May 29, 2026. The filing addresses a strategic decision by the Board of Directors to divest its wholly owned subsidiary, Ekso Bionics, Inc. ("Ekso"), to refocus operations exclusively on its cloud business.

Key Financial Metrics

The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for the reporting period. The document focuses on the announcement of a divestiture plan rather than periodic financial results.

Material Changes

  • Divestiture Plan: The Company committed to a plan to divest Ekso Bionics, Inc., which had not previously been announced as held for sale.
  • Operational Focus: Operations will shift to focus solely on the Company's cloud business.
  • Expected Timeline: The divestiture is expected to be completed during the first fiscal quarter following the announcement.
  • Anticipated Costs: The Company expects to incur material charges, including severance costs, lease termination payments, transaction-related expenses, and other exit costs.

Guidance, Outlook, and Risks

Cost Estimates: The Company is not yet able to make a good-faith estimate of the total amount or range of amounts expected to be incurred for the divestiture. It has committed to amending this report within four business days once estimates are determined.

Risks and Contingencies: Forward-looking statements regarding the divestiture are subject to risks including changes in cost estimates (severance, lease termination), timing and completion of the sale, the ability to successfully execute the wind-down, and general economic conditions. Actual results may differ materially from expectations.

Investor Verification Checklist

  • Verify the amended Form 8-K filing within four business days for specific estimates of exit costs and severance charges.
  • Monitor the timeline for the completion of the Ekso Bionics divestiture in the first fiscal quarter.
  • Assess the impact of the divestiture on the Company's future revenue streams from the remaining cloud business.
  • Review subsequent filings for details on lease termination payments and transaction-related expenses.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.